SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Mar 10, 2014

Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: March 10, 2014 · CIK: 0000921114 · Accession: 0001144204-14-014331

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-23930

Referenced dates: February 24, 2014

Date

March 10, 2014

Author

/s/ Stephen Thau

Form

CORRESP

Company

Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)

Letter

Securities and Exchange Commission Division of Corporation Finance Re: AmpliPhi Biosciences Corporation Amendment No. 1 to Registration Statement on Form 10-12G Filed February 4, 2014 File No. 000-23930

Dear Ms Reischauer:

On behalf of AmpliPhi Biosciences Corporation (the “Company”), the Company hereby requests until March 31, 2014 to respond to the comments to the Company’s Amendment No. 1 to Registration Statement on Form 10-12G contained in the Staff’s letter dated February 24, 2014.

Thank you for your assistance regarding this matter. If you have any questions please contact me at (202) 887-1571 or by email at sthau@mofo.com.

Sincerely,
/s/ Stephen Thau

Show Raw Text

CORRESP
1
filename1.htm

        2000 Pennsylvania Ave., NW

        Washington, D.C.

        20006-1888

        Telephone: 202.887.1500

        Facsimile: 202.887.0763

        www.mofo.com

        morrison &
        foerster llp

        new york, san francisco,

        los angeles, palo alto,

        sacramento, san diego,

        denver, northern virginia,

        washington, d.c.

        tokyo, london, berlin, brussels,

        beijing, shanghai, hong kong,

        singapore

March 10, 2014

BY EDGAR

Amy Reischauer

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

    Re:
    AmpliPhi Biosciences Corporation

    Amendment No. 1 to Registration Statement on Form 10-12G

    Filed February 4, 2014

    File No. 000-23930

Dear Ms Reischauer:

On behalf of AmpliPhi Biosciences Corporation (the “Company”),
the Company hereby requests until March 31, 2014 to respond to the comments to the Company’s Amendment No. 1 to Registration
Statement on Form 10-12G contained in the Staff’s letter dated February 24, 2014.

Thank you for your assistance regarding this matter. If you
have any questions please contact me at (202) 887-1571 or by email at sthau@mofo.com.

Sincerely,

/s/ Stephen Thau

Stephen Thau

    cc:
    Philip J. Young, AmpliPhi Biosciences Corporation

SecProbe.io